CHARLES WYKOFF to Time Factors
This is a "connection" page, showing publications CHARLES WYKOFF has written about Time Factors.
Connection Strength
0.612
-
Pegcetacoplan Treatment for Geographic Atrophy in Age-Related Macular Degeneration Over 36 Months: Data From OAKS, DERBY, and GALE. Am J Ophthalmol. 2025 Aug; 276:350-364.
Score: 0.114
-
Characterizing New-Onset Exudation in the Randomized Phase 2 FILLY Trial of Complement Inhibitor Pegcetacoplan for Geographic Atrophy. Ophthalmology. 2021 09; 128(9):1325-1336.
Score: 0.085
-
Fovea-sparing rhegmatogenous retinal detachments: impact of clinical factors including time to surgery on visual and anatomic outcomes. Graefes Arch Clin Exp Ophthalmol. 2019 May; 257(5):883-889.
Score: 0.074
-
Longitudinal Quantification of Retinal Nonperfusion in the Macula of Eyes With Retinal Vein Occlusion Receiving Anti-VEGF Therapy: Secondary Analysis of the WAVE Randomized Trial. Ophthalmic Surg Lasers Imaging Retina. 2018 04 01; 49(4):258-264.
Score: 0.070
-
Outcomes With As-Needed Aflibercept and Macular Laser Following the Phase III VISTA DME Trial: ENDURANCE 12-Month Extension Study. Am J Ophthalmol. 2017 Jan; 173:56-63.
Score: 0.063
-
What is the optimal timing for rhegmatogenous retinal detachment repair? JAMA Ophthalmol. 2013 Nov; 131(11):1399-400.
Score: 0.051
-
Fovea-sparing retinal detachments: time to surgery and visual outcomes. Am J Ophthalmol. 2010 Aug; 150(2):205-210.e2.
Score: 0.041
-
Pegcetacoplan for Geographic Atrophy Over 30 Months: Data From OAKS, DERBY, and the GALE Long-Term Extension Study. Ophthalmic Surg Lasers Imaging Retina. 2025 Jul; 56(7):398-406.
Score: 0.029
-
MANAGEMENT OF LARGE FULL-THICKNESS MACULAR HOLES: Long-Term Outcomes of Internal Limiting Membrane Flaps and Internal Limiting Membrane Peels. Retina. 2024 07 01; 44(7):1165-1170.
Score: 0.027
-
Two-Year Results of the Phase 3 Randomized Controlled Study of Abicipar in Neovascular Age-Related Macular Degeneration. Ophthalmology. 2021 07; 128(7):1027-1038.
Score: 0.021
-
Efficacy and Safety of Abicipar in Neovascular Age-Related Macular Degeneration: 52-Week Results of Phase 3 Randomized Controlled Study. Ophthalmology. 2020 10; 127(10):1331-1344.
Score: 0.020
-
Randomized Trial of Treat and Extend Ranibizumab With and Without Navigated Laser Versus Monthly Dosing for Diabetic Macular Edema: TREX-DME 2-Year Outcomes. Am J Ophthalmol. 2019 06; 202:91-99.
Score: 0.019